8 months ago
23
Cancers, Vol. 15, Pages 4373: Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer
Cancers doi: 10.3390/cancers15174373
Authors: Carlos Eduardo Bonilla Paola Montenegro Juan Manuel O’Connor Ovidio Hernando-Requejo Enrique Aranda José Pinto Llerena Alejandra Llontop Jorge Gallardo Escobar María del Consuelo Díaz Romero Yicel Bautista Hernández Begoña Graña Suárez Emilio J. Batagelj Ahmad Wali Mushtaq Jesús García-Foncillas
Advances in genomic technologies have significantly improved the management of colorectal cancer (CRC). Several biomarkers have been identified in CRC that enable personalization in the use of biologic agents that have shown to enhance the clinical outcomes of patients. However, technologies used for their determination generate massive amounts of information that can be difficult for the clinician to interpret and use adequately. Through several discussion meetings, a group of oncology experts from Spain and several Latin American countries reviewed the latest literature to provide practical recommendations on the determination of biomarkers in CRC based on their clinical experience. The article also describes the importance of looking for additional prognostic biomarkers and the use of histopathology to establish an adequate molecular classification. Present and future of immunotherapy biomarkers in CRC patients are also discussed, together with several techniques for marker determination, including liquid biopsy, next-generation sequencing (NGS), polymerase chain reaction (PCR), and fecal immunohistochemical tests. Finally, the role of Molecular Tumor Boards in the diagnosis and treatment of CRC is described. All of this information will allow us to highlight the importance of biomarker determination in CRC.
